INDOLENT NON-FOLLICULAR LYMPHOMA
A. Conconi, Ponderano (Italy), et al.
Authors Conclusion from the abstract: In patients with EMZL who received front‐line systemic treatment, POD24 is associated with poorer survival and may represent a useful endpoint in future prospective clinical trials.
A.J. Ferreri, Milan (Italy), et al.
Authors Conclusion from the abstract: Intralesional rituximab is a safe and active treatment in pts with conjunctival indolent lymphoma. The addition of autologous serum is associated with improved response in some cases. Retreatment of local relapses can result in a second long‐lasting response.
A. Bruscaggin, Bellinzona (Switzerland), et al.
Authors Conclusion from the abstract: Genetic analysis of a large cohort of SMZLs cases identified four molecular subtypes characterized by unique deregulated genetic pathways, clinical outcome and potentially a molecular phenotype. These results can provide the basis for proposing the classification of SMZL into provisional molecular subtypes, that may lead to a conceptual edifice for developing precision therapies for SMZL patients.
P.L. Zinzani, Bologna (Italy), et al.
Authors Conclusion from the abstract: PI3K‐delta inhibition with single‐agent umbralisib is active and well tolerated in pts with R/R MZL, achieving durable responses with chemotherapy‐free therapy.
Authors Conclusion from the abstract: Ibrutinib monotherapy can induce durable responses with acceptable toxicity in patients with BNS. Despite symptomatic and radiological improvements in the majority of patients, half of the patients can have persistence of disease in the CSF, and this should not represent treatment failure.
S.P. Treon, Boston, MA (USA), et al.